(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
(PQ
基本信息
- 批准号:9486907
- 负责人:
- 金额:$ 63.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-05-10 至 2021-04-30
- 项目状态:已结题
- 来源:
- 关键词:4T1AdjuvantAdjuvant ChemotherapyAftercareAnxietyAssesBehaviorBindingBioavailableBiological AssayBrainBrain imagingBreast Cancer ModelBreast cancer metastasisCalciumCalcium-Sensing ReceptorsCarboplatinChemicalsChemotherapy-Oncologic ProcedureChronic stressCyclic AMP-Dependent Protein KinasesDataDiseaseDoxorubicinDrug usageEndoplasmic ReticulumExcisionExhibitsFluorouracilFunctional disorderGoalsHeart DiseasesHeart failureHumanImmunologicsImpaired cognitionImpairmentKnock-in MouseLaboratoriesLegal patentLinkLong-Term PotentiationMCF7 cellMDA MB 231Magnetic Resonance ImagingMalignant NeoplasmsManuscriptsMeasuresMemoryMemory impairmentMental DepressionMetastatic Neoplasm to the BoneMethotrexateModelingModificationMorbidity - disease rateMusMuscle WeaknessMuscle functionMuscular DystrophiesMyopathyNeurocognitiveNeuronsOralOxidative StressOxidesPaclitaxelPathologyPatientsPharmaceutical PreparationsPhase II Clinical TrialsPhosphorylationPhosphorylation SitePlacebosPost-Translational Protein ProcessingPost-Traumatic Stress DisordersPreventionProbabilityPublishingRegimenResearch PersonnelRyR1Ryanodine Receptor Calcium Release ChannelSafetySalesSamplingSignal TransductionSkeletal MuscleStressTestingTranslatingUniversitiesWomanadvanced breast cancerage-related muscle losscancer therapychemobrainchemotherapyclinically relevantcognitive functiondesignexecutive functionfield studyfluorodeoxyglucosefluorodeoxyglucose positron emission tomographyhuman modelimaging modalityimprovedin vivomalignant breast neoplasmmorris water mazemouse modelnovelnovel therapeuticsobject recognitionoxidationpreventpublic health relevancereceptor functionresearch clinical testingresponsesmall moleculetreatment strategy
项目摘要
DESCRIPTION (provided by applicant): This application is responsive to the NCI Provocative Question #9 (RFA-CA-15-008). Cognitive dysfunction ("chemobrain") is an important adverse sequel of cancer chemotherapy, the study of which has been identified by the NCI as a poorly understood problem for which current management or treatment strategies are limited or ineffective. Our preliminary data show that neuronal ryanodine receptor/calcium release channels (RyR2) on the endoplasmic reticulum (ER) become oxidized and "leaky" in mice treated with doxorubicin or methotrexate plus 5-FU. These mice exhibit cognitive dysfunction that can be improved using a novel orally available small molecule drug (Rycal, S107) developed by the co-PI that fixes leaky RyR2 channels. The goals of this application are to: (1) establish and characterize a murine model of advanced human breast cancer that can be used to study whether intracellular calcium (Ca2+) leak via oxidized neuronal RyR2 on the ER is a novel mechanism underlying cancer chemotherapy-induced neurocognitive dysfunction; and (2) test whether the novel drug Rycal (S107) that fixes leaky neuronal RyR2 channels in vivo can prevent chemobrain. The proposed studies will have important clinical relevance as the Rycal S107 is in the same chemical class as two closely related Rycals that are currently in clinical testing for heart and muscle disorders, and to date both have excellent safety profiles. S107 has the advantage that it is concentrated >10-fold in the brain. (Although S107 is patented by Columbia University, US 8,710,045, 04/29/14, the drug is available to all investigators and the applicant receives no proceeds from its sale). This application is bolstered by preliminary data showing that commonly used chemotherapeutics cause cognitive dysfunction in C57BL6 mice that can be prevented using the Rycal S107, and by our published data showing that leaky neuronal RyR2 channels can cause stress-induced cognitive dysfunction (post-traumatic stress disorder, PTSD) that can be ameliorated by oral treatment with S107. This application aims to make the novel mechanistic link between chemobrain and PTSD - intracellular Ca2+ leak - and to test a potential novel therapy that prevents this leak and prevents chemobrain.
描述(由申请人提供):本申请是对 NCI 挑衅性问题 #9 (RFA-CA-15-008) 的回应。认知功能障碍(“化学脑”)是癌症化疗的一个重要不良后果,对此的研究已进行。 NCI 认为这是一个人们知之甚少的问题,目前的管理或治疗策略有限或无效。我们的初步数据表明,内质上的神经元兰尼碱受体/钙释放通道(RyR2)。在接受多柔比星或甲氨蝶呤加 5-FU 治疗的小鼠中,网状组织 (ER) 被氧化并“渗漏”。这些小鼠表现出认知功能障碍,可以使用 co-PI 开发的新型口服小分子药物(Rycal,S107)来改善这种功能障碍。该应用的目标是:(1)建立并表征晚期人类乳腺癌的小鼠模型,该模型可用于研究细胞内钙是否存在。 (Ca2+) 通过内质网氧化神经元 RyR2 泄漏是癌症化疗引起的神经认知功能障碍的一种新机制;(2) 测试体内修复泄漏神经元 RyR2 通道的新药 Rycal (S107) 是否可以阻止化疗脑研究。具有重要的临床相关性,因为 Rycal S107 与两种密切相关的 Rycal 属于同一化学类别,这两种药物目前正在进行心脏和肌肉疾病的临床测试,并且迄今为止两者都具有出色的安全性S107 的优点是它在大脑中浓度超过 10 倍(尽管 S107 已获得哥伦比亚大学专利,US 8,710,045,2014 年 4 月 29 日),但该药物可供所有研究人员使用,申请人不会从中获得任何收益。该申请得到了初步数据的支持,该数据显示常用的化疗药物会导致 C57BL6 小鼠认知功能障碍,而使用 Rycal S107 可以预防这种功能障碍,并且通过我们发表的数据显示,渗漏的神经元 RyR2 通道会导致应激性认知功能障碍(创伤后应激障碍,PTSD),而这种情况可以通过口服 S107 治疗来改善。本申请旨在建立化学脑和 PTSD 之间的新机制联系 - 细胞内。 Ca2+ 泄漏 - 并测试一种潜在的新型疗法,以防止这种泄漏并防止化学脑。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
THERESA A GUISE其他文献
THERESA A GUISE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('THERESA A GUISE', 18)}}的其他基金
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
(PQ
- 批准号:
9935202 - 财政年份:2016
- 资助金额:
$ 63.07万 - 项目类别:
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
(PQ
- 批准号:
10328409 - 财政年份:2016
- 资助金额:
$ 63.07万 - 项目类别:
PROSTATE CANCER BONE METASTASES: ROLE OF ADRENOMEDULLIN
前列腺癌骨转移:肾上腺髓质素的作用
- 批准号:
6918192 - 财政年份:2005
- 资助金额:
$ 63.07万 - 项目类别:
PROSTATE CANCER BONE METASTASES: ROLE OF ADRENOMEDULLIN
前列腺癌骨转移:肾上腺髓质素的作用
- 批准号:
7212216 - 财政年份:2005
- 资助金额:
$ 63.07万 - 项目类别:
ENDOTHELIN-1 IN NORMAL AND PATHOLOGICAL BONE REMODELING
内皮素-1 在正常和病理性骨重建中的作用
- 批准号:
7336763 - 财政年份:2005
- 资助金额:
$ 63.07万 - 项目类别:
PROSTATE CANCER BONE METASTASES: ROLE OF ADRENOMEDULLIN
前列腺癌骨转移:肾上腺髓质素的作用
- 批准号:
7032983 - 财政年份:2005
- 资助金额:
$ 63.07万 - 项目类别:
ENDOTHELIN-1 IN NORMAL AND PATHOLOGICAL BONE REMODELING
内皮素-1 在正常和病理性骨重建中的作用
- 批准号:
7005690 - 财政年份:2005
- 资助金额:
$ 63.07万 - 项目类别:
PROSTATE CANCER BONE METASTASES: ROLE OF ADRENOMEDULLIN
前列腺癌骨转移:肾上腺髓质素的作用
- 批准号:
7391126 - 财政年份:2005
- 资助金额:
$ 63.07万 - 项目类别:
ENDOTHELIN-1 IN NORMAL AND PATHOLOGICAL BONE REMODELING
内皮素-1 在正常和病理性骨重建中的作用
- 批准号:
6868304 - 财政年份:2005
- 资助金额:
$ 63.07万 - 项目类别:
相似国自然基金
肿瘤微环境多层次调控的功能化纳米佐剂用于增强膀胱癌放疗疗效的机制研究
- 批准号:82303571
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
靶向FPPS的双磷酸疫苗佐剂的开发
- 批准号:82341040
- 批准年份:2023
- 资助金额:100 万元
- 项目类别:专项基金项目
双重生物响应性自佐剂聚多肽载体构建高效mRNA癌症疫苗
- 批准号:52373299
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
新型免疫调节复合佐剂的机制研究及在疫苗开发中的应用
- 批准号:82341039
- 批准年份:2023
- 资助金额:95 万元
- 项目类别:专项基金项目
皮内接种抗原佐剂复合疫苗跨器官诱导呼吸道黏膜免疫反应
- 批准号:82341042
- 批准年份:2023
- 资助金额:100 万元
- 项目类别:专项基金项目
相似海外基金
Immunomodulatory biomaterial to enhancing T-cell responses to triple negative breast cancer
免疫调节生物材料可增强 T 细胞对三阴性乳腺癌的反应
- 批准号:
10699815 - 财政年份:2023
- 资助金额:
$ 63.07万 - 项目类别:
Developing LG007 as a novel therapeutic agent to treat triple negative breast cancer
开发 LG007 作为治疗三阴性乳腺癌的新型治疗剂
- 批准号:
10889411 - 财政年份:2023
- 资助金额:
$ 63.07万 - 项目类别:
Repurposing Glucosylceramide Synthase to Promote Mitochondrial Lethality and Potentiate an Anti-Tumor Immune Response in Triple-Negative Breast Cancer
重新利用葡萄糖神经酰胺合酶促进线粒体致死性并增强三阴性乳腺癌的抗肿瘤免疫反应
- 批准号:
10656615 - 财政年份:2023
- 资助金额:
$ 63.07万 - 项目类别:
Targeting of eIF4A along with immunotherapy to overcome chemoresistance
靶向 eIF4A 并结合免疫疗法克服化疗耐药性
- 批准号:
10544331 - 财政年份:2022
- 资助金额:
$ 63.07万 - 项目类别:
Targeting eIF4A1 in drug-resistant breast cancer stem-like cells
靶向耐药乳腺癌干细胞中的 eIF4A1
- 批准号:
10680365 - 财政年份:2022
- 资助金额:
$ 63.07万 - 项目类别: